[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t2d\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t2d":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644609","phase-1-bioequivalence-study-of-gzr4-injection-with-different-manufacturing-processes-in-healthy-adult-participants-100644609",false,"NCT07670897","Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants","A Randomized, Open-label, Single-dose Study to Evaluate the Bioequivalence of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants","Inclusion Criteria:\n\n* 1\\. Voluntarily sign the Informed Consent Form (ICF), be willing to accept subcutaneous injection, fully understand the study content, procedures and potential adverse reactions, and be able to comply with the contraindications and restrictions specified in this protocol.\n\n  2\\. Male, aged 18 to 50 years (inclusive) at the time of ICF signing. 3. Body weight ≥ 50 kg and body mass index (BMI) within the range of 18.5 to 24.0 kg\u002Fm² (inclusive) at screening.\n\n  4\\. Male participants of childbearing potential have no plans for conception, voluntarily adopt effective contraceptive measures, and have no sperm donation plans from the date of ICF signing until 4 weeks after dosing.\n\nExclusion Criteria:\n\n* 1\\. Have an allergic constitution, or a history of allergic diseases such as bronchial asthma and eczema (except for mild seasonal allergy); or have a history of severe food allergy (e.g., laryngeal edema, shock); or known allergy, hypersensitivity or intolerance to the investigational medicinal product (IMP) or similar products or their excipients; or have a clinically significant history of drug allergy or atopic allergic diseases.\n\n  2\\. Findings from physical examination, vital signs, routine laboratory tests, 12-lead electrocardiogram (ECG), chest imaging and other assessments at screening are judged to be clinically significant by the investigator.\n\n  3\\. Have special dietary requirements and are unable to comply with the standardized diet.\n\n  4\\. Have a history of needle phobia or blood phobia, have difficulty in blood collection, or cannot tolerate venous puncture for blood sampling.\n\n  5\\. The participant is an employee of the investigator or the study center, or a family member of an employee or the investigator; or the participant has other factors that, in the investigator's opinion, make him\u002Fher unsuitable for participation in the study.",true,"MALE","18 Years","50 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study is a single-center, open-label, randomized, single-dose bioequivalence trial conducted in healthy adult participants.",[28],"T2D","NOT_YET_RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-26","ACTUAL",{"date":35,"type":22},"2026-07-01",{"date":37,"type":22},"2026-07-29",{"name":39,"class":40},"Gan & Lee Pharmaceuticals.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":41},"100593355","fitbit-and-ai-chatbot-in-sedentary-primary-care-patients-with-t2d-100593355","NCT07005362","Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D","Feasibility of Use of Fitbit, Brief DSMES, and Targeted Text Messaging in Sedentary Adults With Type 2 Diabetes in Primary Care Settings","FIT T2D","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes per investigator discretion\n* No more than 20% of the sample will have A1c \\\u003C 7.5% (confirmed by medical record review or an A1c completed within 3 months of the screening visit)\n* Age ≥18 years and ≤ 80 years\n* Does not meet ADA guidelines for physical activity (\\\u003C 150 minutes of aerobic exercise per week defined as any activity where the participant can talk but not sing)\n* Has a smartphone compatible with a Fitbit\n\nExclusion Criteria:\n\n* Completing more than 60 minutes of moderate to vigorous activity per week defined as activity where you cannot sing (moderate) or can't say more than a few words without gasping for breath (vigorous)(14)\n* Any medical condition which, in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and\u002For eating disorders.\n* Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12- months\n* Any planned surgery during the study which could be considered major in the opinion of the investigator\n* Blood disorder or dyscrasia within 3 months before screening, or the use of hydroxyurea, which, in the investigator's opinion, could interfere with the determination of HbA1c\n* Has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study, as they may interfere with the determination of HbA1c.\n* Planning to move from Colorado within 3 months\n* Current Pregnancy or planning on pregnancy in the next 3 months\n* Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision that impacts ability to see FitBit, impaired memory)\n* Unable to speak English as this is a small feasibility study that does not have the resources to adapt the intervention for Spanish\n* Current participation in another diabetes-related clinical trial","ALL","80 Years",{"count":53,"type":22},36,"OBSERVATIONAL","The goal of this observational study is to evaluate the feasibility and acceptability of a 12-week intervention utilizing a Fitbit and artificial intelligence (AI)-delivered diabetes self-management education and support (DSMES) with tailored text messages.\n\nThe main question it aims to answer is:\n\nDoes providing a wearable fitness and activity tracker plus AI-tailored and DSMES improve clinical outcomes for patients with type 2 diabetes?\n\nParticipants will complete a baseline visit, wear a Fitbit and answer text messages for 12-weeks, and complete by a final visit.",[57,58,59,28,60,61,62],"Type 2 Diabetes","Type 2 Diabetes Mellitus (T2DM)","T2DM (Type 2 Diabetes Mellitus)","T2DM","Remote Patient Monitoring","Artificial Intelegence",[64,65,66,67,68,69],"type 2 diabetes","artificial intelligence","fitbit","primary care","remote patient monitoring","physical activity","RECRUITING","2026-05-15",{"date":73,"type":33},"2026-05-19",{"date":75,"type":33},"2025-09-03",{"date":77,"type":22},"2026-08-30",{"name":79,"class":80},"University of Colorado, Denver","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":50,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100610584","potatoes-type-2-diabetes-and-cardiometabolic-health-100610584","NCT07229482","Potatoes, Type 2 Diabetes, and Cardiometabolic Health","Cardiometabolic Effects of a Potato-rich Diet in Older Adults at Increased Risk of Developing Type 2 Diabetes: A Randomized Controlled Feeding Study","Inclusion Criteria:\n\n* Age 50-70 years\n* Weight stable for previous 3 months (±5% body weight)\n* Sedentary to recreationally active\n* ADA-Risk Screener questionnaire score of at least 5\n* No plans to gain or lose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for a 14-week period\n* Verbal and written informed consent\n* Estrogen or testosterone use, lipid-lowering medication and thyroid replacement medication is acceptable, if on stable dose for \\>6 months\n\nExclusion Criteria:\n\n* Body mass index \\>40 m2\u002Fkg\n* Diabetes or diabetes medication\n* Weight loss medication or medication influencing glucose metabolism\n* Antibiotic, prebiotic or probiotic use in prior 3 months\n* TCHOL \\>6.2 mmol\u002FL; TG \\>4.5 mmol\u002FL\n* Blood pressure (BP) \\> 159\u002F99 mmHg or taking antihypertensive medication\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Food allergies or aversions to diet foods provided\n* Estrogen or testosterone usage or lipid-lowering medication usage \\\u003C6 months","70 Years",{"count":90,"type":22},42,[92],"NA","Type 2 diabetes (T2D) is a major chronic health condition which increases risk of coronary artery disease, frailty, cognitive decline, and mortality. Additionally, hypertension is a major comorbidity for individuals with T2D, further increasing the risk of adverse cardiovascular outcomes. The prevalence of both conditions increases with advancing age. There is an urgent need to identify new approaches to prevent the development of T2D and improve cardiometabolic health in older adults 50-70 years of age.\n\nWhole white potatoes are an unprocessed food rich in essential nutrients often under-consumed by Americans, including potassium, fiber, magnesium, vitamins C and B6, and phytochemicals. Each of these nutrients individually are associated with cardiometabolic health benefits. Potatoes account for a significant amount of the intake of these nutrients in the US diet and are well-positioned to be a foundational element of a healthy dietary pattern. However, there are few interventional studies evaluating the effect of potatoes on cardiometabolic health, and the evidence from observational studies is mixed, leaving a significant gap in knowledge regarding the potential for potatoes to be included in healthy dietary patterns.\n\nThe results of our proposed study will provide foundational data that inform future dietary guidelines regarding the inclusion of white potatoes as part of a healthy US dietary pattern.",[28,95,96],"Blood Pressure","Cardiometabolic Health","2026-04-09",{"date":99,"type":33},"2026-04-13",{"date":101,"type":22},"2026-06",{"date":103,"type":22},"2029-03",{"name":105,"class":80},"Virginia Polytechnic Institute and State University"]